Bfsg LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,918 shares of the company’s stock after selling 240 shares during the period. Bfsg LLC’s holdings in AbbVie were worth $4,016,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Bell Private Wealth Management LLC boosted its stake in AbbVie by 39.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 286 shares of the company’s stock worth $43,000 after buying an additional 81 shares during the period. Horrell Capital Management Inc. purchased a new position in AbbVie during the third quarter worth about $45,000. Bourgeon Capital Management LLC boosted its stake in shares of AbbVie by 240.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 340 shares of the company’s stock valued at $53,000 after purchasing an additional 240 shares during the period. Naples Money Management LLC purchased a new position in shares of AbbVie in the fourth quarter valued at approximately $53,000. Finally, Core Wealth Advisors Inc. boosted its stake in shares of AbbVie by 459.7% in the third quarter. Core Wealth Advisors Inc. now owns 347 shares of the company’s stock valued at $52,000 after purchasing an additional 285 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total value of $9,184,047.70. Following the sale, the executive vice president now directly owns 243,944 shares in the company, valued at approximately $42,375,512.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Perry C. Siatis sold 13,753 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $177.51, for a total value of $2,441,295.03. Following the sale, the executive vice president now directly owns 28,173 shares in the company, valued at approximately $5,000,989.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Azita Saleki-Gerhardt sold 52,870 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total transaction of $9,184,047.70. Following the completion of the transaction, the executive vice president now directly owns 243,944 shares of the company’s stock, valued at approximately $42,375,512.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 383,324 shares of company stock worth $67,780,003. Corporate insiders own 0.25% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on AbbVie
AbbVie Stock Performance
ABBV traded down $1.55 during trading on Thursday, hitting $166.25. The stock had a trading volume of 1,401,016 shares, compared to its average volume of 5,541,868. The company has a debt-to-equity ratio of 5.02, a quick ratio of 0.76 and a current ratio of 0.87. The firm has a market capitalization of $294.37 billion, a P/E ratio of 60.97, a PEG ratio of 2.16 and a beta of 0.58. The company’s 50-day moving average price is $175.13 and its 200 day moving average price is $160.62. AbbVie Inc. has a twelve month low of $130.96 and a twelve month high of $182.89.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, February 2nd. The company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.76 by $0.03. The company had revenue of $14.30 billion for the quarter, compared to analysts’ expectations of $14.02 billion. AbbVie had a net margin of 8.95% and a return on equity of 162.28%. AbbVie’s revenue was down 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.60 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 11.19 EPS for the current fiscal year.
AbbVie Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be given a dividend of $1.55 per share. The ex-dividend date is Friday, April 12th. This represents a $6.20 annualized dividend and a dividend yield of 3.73%. AbbVie’s payout ratio is currently 227.11%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Stories
- Five stocks we like better than AbbVie
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Hasbro’s Management Made All the Right Calls This Quarter
- The Most Important Warren Buffett Stock for Investors: His Own
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Using the MarketBeat Dividend Yield Calculator
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.